diabetestalk.net

Animas Insulin Pump Supplies

Johnson & Johnson Exits Insulin Pump Market Due To Increased Competition

Johnson & Johnson Exits Insulin Pump Market Due To Increased Competition

Animas Corporation, which is part of the Johnson & Johnson (J&J) Diabetes Care Companies, recently announced that it would close its doors and stop selling insulin pumps, including the Animas Vibe and OneTouch Ping, according to a press release. Animas reported they have selected Medtronic plc to help patients and providers with this transition. Patients who currently have an Animas pump will be offered a Medtronic pump, according to the release. The company plans to offer customer service, training, and warranty support during the transition period to ensure patients are achieving the optimal results. Additionally, patients will still be able to access supplies used with the pumps. “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition,” said Valerie Asbury, general manager of Animas. “Our number one priority is ensuring patients have a seamless experience as they transition to Medtronic. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident they will provide outstanding support to our patients and their healthcare teams.” Currently, more than 90,000 patients use Animas pumps and products. The manufacturer advises that patients and providers should explore their transition options. “We are incredibly grateful to our patients and healthcare partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years,” Asbury said. “With changing needs of customers, rapidly evolving market dynamics, and increased competitive pressures, it proved too difficult to sustain the insulin pump business and we decided to pursu Continue reading >>

Usa Insulin Pump Market, 2022: Leading Companies Are Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training Model

Usa Insulin Pump Market, 2022: Leading Companies Are Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training Model

Dublin, Aug. 22, 2017 (GLOBE NEWSWIRE) -- The "USA Insulin Pump Market & Users, CGM (Continuous Glucose Monitoring) Market & Users, Reimbursement Policy (By States), Diabetes (Type 1 & 2) Population, Deal Types, Clinical Trials & Forecast" report has been added to Research and Markets' offering. The USA insulin pump market is anticipated to cross US$ 5 Billion by the end of 2022 Insulin Pump has now become a well-known and a favored device for Type 1 diabetes patients in the United States. The easiness of using insulin pump is gaining comprehensive recognition in the market as insulin delivery systems. "United States CGM (Continuous Glucose Monitor) Market to be more than US$ 2 Billion in Future" CGM (Continuous Glucose Monitor) is extremely important across all age groups to manage diabetes efficiently. In the United State, the market of CGM has a huge potential in coming years. From the year 2009 to 2016, Continuous Glucose Monitor users have grown to 35 percent. Many private insurers have started reimbursing CGM based on certain criteria in the United States. Many experts think that CGM is the best tool for diabetes management. For those having several diabetes complications, Continuous Glucose Monitor is very much compatible with that. "In USA by States, Reimbursements of Insulin Pumps, CGM, Diabetes Supplies" According to Renub Research report, we have enclosed many State sponsored programmes, which covers insulin pumps under equipment and supplies. The report also provides reimbursement details on the CGM either by the federal health plan or by the State-sponsored health plan. Nearly every state facilitates diabetes supplies to their city but not all state provides insulin pump. For the state-regulated health insurance policies, all the state law diabetes mandates Continue reading >>

Breaking News In Diabetes – Animas Halts Insulin Pump Production

Breaking News In Diabetes – Animas Halts Insulin Pump Production

This past Thursday, October 5, 2017, the Diabetes community was rocked by the announcement that Animas Corporation will no longer be manufacturing its insulin pumps, the Animas Vibe and One Touch Ping. The companies decision affects more than 90,000 Animas pump users in the US and Canada. Sale of the pumps world-wide will continue for now. Continuous Glucose Monitoring (CGM) products manufactured by Animas will continue. Animas partners with Medtronics Animas will be partnering with Medtronics to switch patients to their pumps instead over a period of time. Animas is assuring patients that they will have the same service for their existing insulin pumps, but in some Type 1 communities, reports are being shared that people have already lost their insulin pump representatives. I advise reading the following pieces: What does the announcement mean for pumpers in the diabetes community? All over Facebook, the Type 1 community is worried, as corporate decisions affect patient decisions, and quality of life. If you go to the Animas website, you will see the announcement, along with important links about the transition, and phone numbers to call Medtronics to discuss your options. Will there be time before I have to switch my pump to Medtronics? Animas promises to continue warranty service and support, and to continue to provide all pump supplies needed through the transition. For warranties that go out after September 30, 2019, patients should receive a contact from Medtronics to transfer to their pump, the Medtronics 630G, at no additional cost. If you have a pump where the warranty expired earlier before September 30, 2019, then Animas says that you are still under their warranty through the transition, and will still have serviced. They say it’s business as usual, and to Continue reading >>

Johnson & Johnson's Animas To Shut Down Ops And Exit Insulin Pump Biz, 410 Jobs Affected

Johnson & Johnson's Animas To Shut Down Ops And Exit Insulin Pump Biz, 410 Jobs Affected

October 5, 2017 By Alex Keown, BioSpace.com Breaking News Staff CHESTERBROOK, Pa. – Animas Corporation, a Johnson & Johnson division focused on diabetes care, is exiting the space and shutting down operations and laying off 410 employees. This morning, Pennsylvania-based Animas Corporation will discontinue the manufacturing and sale of the insulin pumps it manufactures, Animas Vibe and One-Touch Ping. The two pumps are used by approximately 90,000 diabetes patients. In a statement issued this morning, Animas said patients using its products will be allowed to transition their needs to rival company Medtronic plc . Animas said it will continue to provide customer service, training and warranty support to insulin-pump customers through a transition period, although how long that period will be was not disclosed. Johnson & Johnson announced earlier this year that it was exploring strategic options to maximize shareholder value and one of those was the possible sale of its diabetes care business. In January, J&J said it planned to seek a possible sale, joint venture or operating partnerships for LifeScan Inc., Animas and Calibra Medical Inc.. as part of a plan to spark growth. This morning, Johnson & Johnson said it will continue to evaluate potential strategic options for LifeScan, Inc. and its blood glucose monitoring OneTouch brand of products. In its statement announcing the close of Animas, the company said the decision to shutter Animas was due to the changing needs of customers, market dynamics and increased competition. The combination of challenges made it “too difficult to sustain the insulin pump business” and the decision was made to close down Animas. Animas is moving quickly with its decision. As of today, the company has discontinued sales of its insuli Continue reading >>

Animas To Discontinue Manufacturing And Sale Of Insulin Pumps

Animas To Discontinue Manufacturing And Sale Of Insulin Pumps

Animas Corporation has announced that it will discontinue the manufacturing and sale of Animas® Vibe® and OneTouch Ping® insulin pumps, close operations and exit the insulin pump business. Animas has selected Medtronic as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers. Patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump. Patient safety and continuity of care is of utmost importance and Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used in conjunction with the Animas® Vibe® and OneTouch Ping® insulin pumps, through a transition period. “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition,” said Valerie Asbury, General Manager of Animas Corporation. “Our number one priority is ensuring patients have a seamless experience as they transition to Medtronic. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident they will provide outstanding support to our patients and their healthcare teams.” “We are incredibly grateful to our patients and healthcare partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years,” Asbury said. “With changing needs of customers, rapidly evolving market dynamics, and increased competitive pressures, it proved too difficult to sustain the insulin pump business and we decided to pursue an exit of the business. This decision was extremely difficult and comes following the extensive exploration Continue reading >>

12/19/2017 Tech Update: Notice For Animas Pump Users

12/19/2017 Tech Update: Notice For Animas Pump Users

Attention Animas Pump Users: Animas has announced the intended discontinuation of manufacturing The Animas® Vibe® and OneTouch Ping® insulin pumps. Animas has pledged to continue customer support and training, as well as provide pump supplies associated with the discontinued devices for a period of time and only while the insulin pump is under warranty. Through Sept. 30, 2019, Medtronic will provide Animas supplies to those who continue using these insulin pumps under warranty. Patients and caregivers may explore insulin pump transition options by speaking with their Berrie Center providers, visiting www.medtronicdiabetes.com/Animas or contacting Medtronic at (855) 322-9568. Patients and caregivers can also visit www.animaspatientsupport.com for more information. In order to be better prepared for this transition, we encourage all patients with Animas insulin pumps to contact Animas to determine when their current system is out of warranty. Continue reading >>

Here For You.

Here For You.

Animas recently announced it has discontinued sales of its pumps in the United States and Canada and will close its pump business. As Animas’ partner-of-choice for this transition, our Medtronic team is ready to help. We know that when it comes to your diabetes management needs, it’s a very personal decision and our experienced team is here to support you through every step in the process. Over the past 30 years, we have set out to transform diabetes care to enable greater freedom and better health through innovations across the care continuum, through advanced pump and CGM therapies, and comprehensive services like our StartRight Program and 24-hour Helpline that has served over 1.2 million people in more than 100 countries worldwide to date. In fact, our unparalleled service is the #1 reason our customers stay with us. Guided by our Medtronic Mission, we continually strive to address unmet needs through best-in-class solutions for people with diabetes around the world. Stay Connected We make it easy for our customers to stay connected with us and others in the Diabetes Online Community. Through our social channels, we share helpful diabetes tips, stories and perspectives from the community as well as from our Medtronic team. We count on our robust online community to give us feedback and help shape the solutions we innovate to help transform diabetes care so we invite you to join the conversation and stay connected with us! If you need pump supplies or customer support for your current Animas pump, you can continue to use the same methods you do today – nothing changes for now. As always, an Animas team member can be reached at 877-937-7867 (US) and 866-406-4844 (Canada). If your pump warranty has expired, you’re at risk of going off therapy should something h Continue reading >>

The Future For Insulin Pump Companies: Who Will Survive?

The Future For Insulin Pump Companies: Who Will Survive?

www.diabeticinvestor.com As problems for Tandem continue, and with Johnson & Johnson abandoning the insulin pump market, it’s beginning to dawn on some people that we soon could live in a world with just two insulin pump companies – Medtronic and Insulet. [Editor’s Note: Johnson & Johnson reached out to us with the following information: “Animas continues to manufacture, deliver and support its products and provide the service our patients expect. We remain committed to our patients, and we intend to honor our warranty and do not anticipate any interruptions to patients’ pump therapy. If patients or potential patients have any concerns, they can contact Animas online or at 1-877-YES-PUMP.”] Ok, to be fair, Roche also has a pump, but their market presence is lacking. Also, to be fair, Bigfoot is working on a system, but it isn’t here yet. Plus, there is growing belief that patients can achieve optimum control using a CGM smart insulin pen system. Given where things stand today, the real possibility exists that when it comes to insulin pumps, patient choice will be very limited. This was a fear expressed by many when Medtronic signed an exclusive deal with UnitedHealthcare. Yet this agreement is not the cause of limited patient choice. Poor strategy is the real reason, as both Tandem and J&J have made mistakes that have put them in their current positions. Now, I will not list these mistakes as it serves no useful purpose; there is no need to go backward. What I will do, however, is offer a path forward for any company that is bold enough to take on Medtronic. Keep in mind that Diabetic Investor has been covering Medtronic since it was known as MiniMed and no one, and I mean no one, has come close to giving them a run for their money – EVER. The insulin pu Continue reading >>

Customers In Countries Outside U.s. And Canada

Customers In Countries Outside U.s. And Canada

Animas Corporation intends to exit the insulin pump business and discontinue the manufacturing and sale of Animas® Vibe® and OneTouch Ping® insulin pumps. This decision was extremely difficult and comes following an extensive exploration of all viable other options for the Animas business. We have selected Medtronic as our partner-of-choice to facilitate a seamless insulin delivery system transition period. One of the reasons we chose Medtronic as our partner-of-choice is because of its strong track record providing outstanding patient care and support. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident that they will provide outstanding support to our patients and their care teams. If you are currently using an Animas pump and pump supplies, you will continue to receive pump support and services. Specifically, Animas will continue to provide customer service and warranty support, including providing pump supplies that are used in conjunction with the Animas® Vibe® and OneTouch Ping® insulin pumps, through a transition period. As part of our continued commitment to patient care, Animas will honor pump warranties. We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure patients and their care teams that we will be there, every step of the way, throughout this process. For patients, caregivers and healthcare providers in the U.S. and Canada, this announcement means: Animas has discontinued the sale of all Animas® Vibe® and OneTouch Ping® insulin pumps effective immediately. If you are on a pump with a warranty that expires on or after September 30, 2019, you or your pump supplier will be contacted by a member of the Medtronic tran Continue reading >>

Animas Corporation To Close Operations And Exit Insulin Pump Market

Animas Corporation To Close Operations And Exit Insulin Pump Market

Company will work with Medtronic as a partner-of-choice to help ensure a smooth transition for patients on insulin pumps CHESTERBROOK, Pa., Oct. 5, 2017 /PRNewswire/ -- Animas Corporation, one of the Johnson & Johnson Diabetes Care Companies, today announced that it intends to discontinue the manufacturing and sale of Animas® Vibe® and OneTouch Ping® insulin pumps, close operations and exit the insulin pump business. Animas has selected Medtronic plc (NYSE: MDT), a world leader in diabetes, as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers. Patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump. Patient safety and continuity of care is of utmost importance and Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used in conjunction with the Animas® Vibe® and OneTouch Ping® insulin pumps, through a transition period. "We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition," said Valerie Asbury, General Manager of Animas Corporation. "Our number one priority is ensuring patients have a seamless experience as they transition to Medtronic. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident they will provide outstanding support to our patients and their healthcare teams." "We are incredibly grateful to our patients and healthcare partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years," Asbury said. "With changing needs of customers, rap Continue reading >>

Insulin Pump Supplies & Insurance Companies: Short Changed In Translation~

Insulin Pump Supplies & Insurance Companies: Short Changed In Translation~

This post re: Insulin pump supplies and health insurance B.S. is a bit long, but I think it's important & I hope you do too~ ######## At the end of December and after a string of iffy (and by iffy I’m talking about the sticky part not being so sticking) infusion sets, I called up Medtronic’s Customer Service, told them the issues I was having and provided them with infusion set box lot number. Medtronic listened to my complaints, sympathized with them and after a series of questions regarding the LOT & REF numbers and infusion set insertion, rectified the situation IMMEDIATELY by sending me a box of replacement infusion sets, free of charge. I understand that things happen sometimes in life and with supplies - I totally get it. I really appreciated the fact that Medtronic CS listened to my issues & analyzed the problem and sent me out a new box of supplies. The new box of infusion sets worked like a charm. Sidebar: Regardless of your pump brand/CGM/test strip/insulin brand, if you’re having issues with anything - you need to let the company know what’s going on. They can’t help you if you don’t pick up the phone. Also, they want to document any issues their customers are having & fix the problem, ASAP. If you don't tell them you're having issues, how are they going to know and then fix said issues? In mid January I received my tri monthly order of pump supplies from Medtronic. I cracked open the box and instead of emptying it out like I normally would, I decided to get all organized ( my friend Susan Weiner would be proud), took out the bubble wrap and placed the opened box of replacement infusion sets from December in the box, along with 2 extra boxes of insulin reservoirs a friend had given me after she decided to go on a pump vacation. My pump supplies we Continue reading >>

Medtronic Service And Support For Animas Insulin Pump Customers

Medtronic Service And Support For Animas Insulin Pump Customers

As you may have read, this morning Animas announced its decision to close its insulin pump business, discontinuing the manufacturing and sale of all Animas® Vibe® and OneTouch Ping® insulin pumps in the US and Canada. In addition, Animas has selected Medtronic to be its partner-of-choice to support Animas customers through this time. Our top priority is to ensure that people using Animas pumps can stay on pump therapy and receive the supplies and support they need, while continuing to support our existing Medtronic customers. If you’re a Medtronic pumper, this does not impact you at all. You are, and always will be, invaluable members of our community. Whether you’ve been with us for 30 years or are a new addition to the family, we are inspired by you. You’re the reason we come to work every day excited to develop innovative products and services that help you live well and chase your dreams (whatever that may be). If you currently use an Animas insulin pump, I want to welcome you to the Medtronic family and assure you that we know the technology you use to manage your diabetes is an important, personal decision. We are here for you and committed to supporting you every step of the way. Nothing will change for you right away. However, here’s what this announcement means for you over the coming months: If your Animas pump is currently out of warranty, you can visit medtronicdiabetes.com/animas to explore your upgrade options. Please keep in mind that this arrangement does not impact Animas customers outside of the US or Canada at this time. It also does not impact those using OneTouch blood glucose meters. Again, please accept our warmest welcome to the Medtronic family. We’re honored to have the opportunity to extend to you the service and support that we Continue reading >>

Animas To Close, Lay Off 400 Workers In Tredyffrin

Animas To Close, Lay Off 400 Workers In Tredyffrin

TREDYFFRIN >> Animas Corp. said Thursday it intends to exit the insulin pump business and discontinue the manufacturing and sale of its Vibe and OneTouch Ping insulin pumps. The decision will affect around 400 workers nationally, about half of whom work at the company’s Chesterbrook and West Chester area operations. “This decision was extremely difficult and comes following an extensive exploration of all viable other options for the Animas business,” the company said in announcing the move. “We have selected Medtronic as our partner-of-choice to facilitate a seamless insulin delivery system transition period. One of the reasons we chose Medtronic as our partner-of-choice is because of its strong track record providing outstanding patient care and support. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident that they will provide outstanding support to our patients and their care teams.” The company said patients in the U.S. and Canada using Animas pumps and pump supplies will continue to receive support and services for a time. Some 90,000 patients are estimated to use the pumps. It also will honor pump warranties. Advertisement “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure patients and their care teams that we will be there, every step of the way, throughout this process,” the company said in the statement. Patients using a pump with a warranty that expires on or after Sept. 30, 2019, will be contacted by a member of the Medtronic transition team concerning the option to transfer to a Medtronic 630G insulin delivery system at no cost, Animas said. Animas will continue to honor warranties that expire before Sept. Continue reading >>

Johnson & Johnson's Animas To Close Operations, Exit The Insulin Pump Business

Johnson & Johnson's Animas To Close Operations, Exit The Insulin Pump Business

Johnson & Johnson's Animas Corp. said Thursday it plans to close operations and exit the insulin pump business. The company will discontinue the manufacturing and sale of its Animas, Vibe and OneTouch Ping insulin pumps. Animas said Medtronic PLC MDT, +0.21% will help facilitate a transition for the 90,000 patients who use Animas pumps, and who will be offered the option to transfer to a Medtronic pump. Animas employs 410 people around the world. The move comes as part of J&J's strategic review announced in January, in which it is continuing to evaluate options for LifeScan, a blood glucose monitoring company with the OneTouch brand of products. J&J's stock was inactive in premarket trade. It has slipped 0.6% over the past three months, while the SPDR Health Care Select Sector ETF XLV, +0.19% has gained 3.9% and the S&P 500 SPX, +0.08% has advanced 4.3%. Continue reading >>

Our Response To Animas’ Exit From The Insulin Pump Market

Our Response To Animas’ Exit From The Insulin Pump Market

We believe competition is important to push companies to constantly innovate for people with diabetes and provide the highest level of quality and service at a reasonable price. For that reason, we are disappointed by this week’s news that Animas is exiting the U.S. pump market and have designated Medtronic as a preferred partner to transition customers. Not only have patients lost a popular pump option this week, we also believe this kind of arrangement has the potential to limit patient access to evolving technology in the future. We feel it’s important to point out that Animas customers are not obligated to get their next pump from any specific company, and should not make their next pump decision by default, based on this new arrangement. Having diabetes isn’t a choice. How people manage it should be. We encourage Animas customers to explore their options and choose the pump that best meets their needs. Tandem is now the only company currently offering an insulin pump that integrates with the Dexcom G5 Mobile CGM, approved for making treatment decisions without fingersticks (only two fingerstick CGM calibrations required per day). Dexcom sensor integration is a feature many chose Animas for with the launch of their original VIBE Pump with Dexcom G4 PLATINUM CGM integration and the anticipated VIBE Plus Pump with Dexcom G5 Mobile CGM. It is also the reason so many patients have already chosen Tandem’s t:slim X2 Pump. We welcome the opportunity to help any current Animas customers continue enjoying the benefits of an insulin pump with Dexcom sensor integration when they are ready for a new pump. We know change can be stressful, particularly when it is unexpected, and we are here to help in whatever way we are able. For a limited time, eligible Animas pump user Continue reading >>

More in diabetes